|Page (1) of 1 - 12/12/17||email article||print page|
INNATE PHARMA : UPCOMING INVESTOR CONFERENCES(December 12, 2017)
upcoming investor conferences
Marseille, France, December 12, 2017, 7:00 AM CET
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor events during the first quarter of 2018:
- J.P. Morgan Annual Healthcare Conference - San Francisco, January 8-10, 2018
- Oddo BHF Forum - Lyon, January 11-12, 2018
- Innate Pharma R&D Day - London, March 8, 2018
The Company will host an
R&D Day on March 8th, 2018,
in London, UK, from 1:00 to 5:00 pm GMT.
Innate Pharma's management team will highlight Innate's leading scientific role in immuno-oncology and its emerging proprietary portfolio, provide a more in-depth look at lead projects, IPH4102 and IPH5401, and their commercial potential.
The event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact Consilium Strategic Communications, at [email protected].
Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (http://www.innate-pharma.com/en/investors ).
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.
The Company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.
Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.
Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
| ISIN code|
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Dr Markus Metzger / Jérôme Marino
Tel.: +33 (0)4 30 30 30 30
| International Media |
Consilium Strategic Communications
Mary-Jane Elliott /
Tel.: +44 (0)20 3709 5700
Mob: +33 (0)6 10 54 36 72